Ajanta Pharma's shares dropped by 0.2% to ₹2,786.8 following the disclosure of five USFDA observations after an inspection at their Paithan plant. The decline marks a 5% drop year-to-date.

Ajanta Pharma's Maharashtra facility has received five FDA observations following a recent inspection. The company is working promptly to address these issues and will disclose the findings publicly for transparency.